Chamrosh Startup is supported by a passionate team of renown academics, experts, researchers, co-creators and partners.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
President & Chief Executive Officer
Andrei Floroiu has been a member of our board of directors since April 2020 and the CEO since 15th June 2020. Most recently, Andrei was with Agenus, Inc., an immuno-oncology and vaccine pioneer, where he held executive positions and was responsible for structuring strategic partnerships and other transactions, including the origination and execution of a $115 million royalty transaction based on GSK’s Shingrix vaccine.
Prior to Agenus, Andrei was a Managing Director at Exigo Capital providing strategic advice to C-suite executives and Boards. He also brings prior biopharma investment and advisory experience with The Invus Group, a leading healthcare investment firm, and McKinsey & Co, the leading management consultancy.
Andrei holds an MBA from the Wharton School, an MSc. from the University of Maryland, and a degree in Engineering from the Politechnica University of Bucharest.
Chamrosh Technologies is a data-backed intelligent system for identifying, storing, and verifying the authenticity of Persian rugs
Copy Rights © 2018-2022 Chamrosh Technologies | All rights reserved
